ERBB2 and neoplasm: The HER-2/neu epitope, spanning amino acids 369–377 (HER-2(9369)), was first described by Fisk et al (1995) as an immunodominant human leucocyte antigen (HLA)-A2-restricted epitope that was recognised by four out of four ovarian tumour-associated lymphocytes, as well as tumour reactive clones.